# Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

> **NCT02343120** · PHASE1,PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 385 (actual)

## Conditions studied

- B-cell Malignancies

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT02343120
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-04
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2022-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343120, "Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT02343120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*